Product label: Temozolomide Capsules, 5mg, packaged in 5-capsule bottles, Rx only, Manufactured for: Rising Pharmaceuticals, Inc., Allendale, NJ 07401, Country of origin: Taiwan, NDC 16571-816-51.
Published March 11, 2026 · Recall initiated: March 3, 2026
Summary
FDA records drug Class II recall D-0384-2026, published March 11, 2026 and initiated March 3, 2026. Recalling firm: Rising Pharma Holding, Inc.; Status: Ongoing; Reported quantity: 1200 bottles; Lot: Lot #: 1TM0524003A, Exp. Date 09/2026. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Failed Impurities/Degradation Specifications: An out-of-specification result observed during 9th-month long term stability testing
What to do
Voluntary: Firm initiated · Letter
Get an email if TEMOZOLOMIDE has another recall
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Brand
- TEMOZOLOMIDE
- Manufacturer
- Rising Pharma Holding, Inc.
- Distributor
- Nationwide within the U.S
- Lot
- Lot #: 1TM0524003A, Exp. Date 09/2026.
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDAMidodrine Hydrochloride Tablets, USP, 5 mg, 50 Tablets (5 x 10 blister packs), Rx only, Packaged andMarch 11, 2026
- FDAFIVE-STAR, VASOCAINE Spray, (Lidocaine HCl 4%, Racepinephrine HCl 0.01%), 4oz bottles, Distributed By: DermalMarch 11, 2026
- FDANilotinib Capsules, 200 mg per capsule, packaged in cartons, Rx only, Manufactured for: Cipla USA, Inc., 10March 11, 2026
- FDAMAXIMUM, ZONE 1, 4% Lidocaine Cream, 1/2 oz bottles, Distributed By: Dermal Source, Portland, OR 97232, NDCMarch 11, 2026
- FDATemozolomide Capsules, 180 mg, packaged in a) 5-count bottle (NDC 67877-541-07), b) 14-count bottle (NDCJuly 31, 2019
- FDATemozolomide Capsules, 100 mg, packaged in a) 5-count bottle (NDC 67877-539-07), b) 14-count bottle (NDCJuly 31, 2019
Questions about this recall
Was Product label: Temozolomide Capsules, 5mg, packaged in 5-capsule bottles, Rx only, Manufactured for: Rising Pharmaceuticals, Inc., Allendale, NJ 07401, Country of origin: Taiwan, NDC 16571-816-51. recalled?
Yes. FDA published recall D-0384-2026 on March 11, 2026. Reported hazard: Failed Impurities/Degradation Specifications: An out-of-specification result observed during 9th-month long term stability testing
What should I do if I have this product?
Voluntary: Firm initiated · Letter
How do I know if my unit is part of the recall?
Compare your product details with the notice. Brand: TEMOZOLOMIDE.